PFE's Etrasimod is taking aim at BMY's Zeposia. I'm long both companies, but I should probably root for Zeposia insofar as it figures to be a larger proportion of total corporate sales.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”